Brazilian and French researchers have developed an imaging-based AI tool to predict how multiple sclerosis patients will respond to natalizumab treatment.
Key Details
- 1Combines high-content cell imaging and machine learning to analyze patient blood samples before natalizumab therapy.
- 2Study used over 400 cell morphological features, with 130 key characteristics for prediction.
- 3Tool achieved 92% accuracy in discovery and 88% in validation cohorts for predicting drug response.
- 4Non-responders showed distinct actin remodeling and cell morphology (more elongated CD8+ T cells).
- 5Findings published in Nature Communications, suggesting potential for broader disease and drug applications.
Why It Matters
This research demonstrates how imaging AI and advanced cell analysis can enable more personalized and effective treatment strategies in neurology. Such approaches could optimize resource use, reduce side effects, and accelerate precision medicine adoption in radiology and adjacent fields.
Source
EurekAlert
Related News
•EurekAlert
FDA Approves Johns Hopkins AI Tool for Early Sepsis Detection
FDA clears an AI-driven system developed by Johns Hopkins to detect sepsis up to 48 hours earlier and reduce mortality rates.
•EurekAlert
New AI Vision-Language Model Enhances Chest CT Diagnostics
Researchers developed an interpretable AI model that uses visual question answering to generate detailed diagnostic findings from chest CT scans, aimed at improving lung cancer diagnosis.
•EurekAlert
Optical AI Chip Boosts Real-Time Dry Eye Gland Diagnosis Accuracy
A new metasurface spectral AI chip enables rapid, accurate diagnosis of meibomian gland dysfunction (MGD) from tissue samples, achieving 96.22% accuracy.